Physician profile
Lon Abney
NPI 1962883272
$2,744.20
in general payments reported to CMS, 2019-2025
16 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $1,025 · 2021: $444 · 2022: $487 · 2023: $106 · 2024: $341 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $775.78 | 2019-2024 | Lifevest |
| Abbott Laboratories | $654.21 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $364.43 | 2019-2024 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $173.81 | 2020-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $138.05 | 2020-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $137.50 | 2019-2024 | |
| Edwards Lifesciences Corporation | $92.19 | 2025 | Sapien 3 Ultra Resilia |
| Astellas Pharma US INC | $89.99 | 2020 | |
| Boston Scientific Corporation | $83.86 | 2022 | |
| Amgen INC. | $82.92 | 2023-2024 | Repatha |
| Akcea Therapeutics, INC. | $51.60 | 2019-2020 | |
| Pfizer INC. | $28.31 | 2025 | |
| Medtronic, INC. | $22.00 | 2021 | |
| Abiomed | $21.81 | 2020 | |
| Genzyme Corporation | $15.71 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lon Abney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.